← brief for 2026-08-14 · Slowing decline

GLP-1 analogues in patients with type 2 diabetes and chronic kidney disease: Benefits beyond glycemic control

Paper B Peer reviewed Small trial

Key takeaways

This review looked at GLP-1 drugs in patients with diabetes and kidney disease. The drug group had better kidney function than the placebo group at 2 years, but this was a small study with only 100 patients. Better kidney function means slower decline in glomerular filtration rate (eGFR).

Who did this work

Marcella Culau Vieira · Vitória Aparecida Cunha · Rodrigo Gonçalves Corrêa · Mateus de Paula Fonseca Damacena · Natália Elisabeth Wagner Müller · Rafaela dos Santos Bertagli · Rafael Pedro Roewer

Source

Paper · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-08-13
https://doi.org/10.70164/ihsr.v2i4.211